These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 29543624)
21. A head-to-head comparison of [ Zheng J; Wang G; Ru Q; Yang Y; Su L; Lv W; Ke C; Wang P; Liu X; Zhang L; Liu F; Miao W Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3386-3399. PubMed ID: 38724654 [TBL] [Abstract][Full Text] [Related]
22. Detection of subcentimeter metastatic cervical lymph node by 18F-FDG PET/CT in patients with well-differentiated thyroid carcinoma and high serum thyroglobulin but negative 131I whole-body scan. Kunawudhi A; Pak-art R; Keelawat S; Tepmongkol S Clin Nucl Med; 2012 Jun; 37(6):561-7. PubMed ID: 22614187 [TBL] [Abstract][Full Text] [Related]
23. Somatostatin receptor imaging with [ Zhao L; Pang Y; Wang Y; Chen J; Zhuang Y; Zhang J; Zhao L; Sun L; Wu H; Chen X; Lin Q; Chen H Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1360-1373. PubMed ID: 34665275 [TBL] [Abstract][Full Text] [Related]
24. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Conry BG; Papathanasiou ND; Prakash V; Kayani I; Caplin M; Mahmood S; Bomanji JB Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):49-57. PubMed ID: 19662413 [TBL] [Abstract][Full Text] [Related]
25. High Level of Agreement Between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases. Ruhlmann M; Jentzen W; Ruhlmann V; Pettinato C; Rossi G; Binse I; Bockisch A; Rosenbaum-Krumme S J Nucl Med; 2016 Sep; 57(9):1339-42. PubMed ID: 27151981 [TBL] [Abstract][Full Text] [Related]
26. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with Sampathirao N; Basu S J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019 [TBL] [Abstract][Full Text] [Related]
27. The role of tumour biomarkers in choosing the appropriate positron emission tomography imaging in follow-up of medullary thyroid cancer. Şahin E; Elboğa U J Med Imaging Radiat Oncol; 2020 Dec; 64(6):756-761. PubMed ID: 32656989 [TBL] [Abstract][Full Text] [Related]
28. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627 [TBL] [Abstract][Full Text] [Related]
29. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET. Van Nostrand D; Khorjekar GR; O'Neil J; Moreau S; Atkins FB; Kharazi P; Mete M; Chennupati SP; Burman KD; Wartofsky L J Nucl Med; 2012 Mar; 53(3):359-62. PubMed ID: 22315442 [TBL] [Abstract][Full Text] [Related]
30. Comparison of 68Ga PET/CT to Other Imaging Studies in Medullary Thyroid Cancer: Superiority in Detecting Bone Metastases. Castroneves LA; Coura Filho G; de Freitas RMC; Salles R; Moyses RA; Lopez RVM; Pereira MAA; Tavares MR; Jorge AAL; Buchpiguel CA; Hoff AO J Clin Endocrinol Metab; 2018 Sep; 103(9):3250-3259. PubMed ID: 29846642 [TBL] [Abstract][Full Text] [Related]
31. The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan. Stangierski A; Kaznowski J; Wolinski K; Jodlowska E; Michaliszyn P; Kubiak K; Czepczynski R; Ruchala M Nucl Med Commun; 2016 Sep; 37(9):935-8. PubMed ID: 27383190 [TBL] [Abstract][Full Text] [Related]
32. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management. Kunikowska J; Lewington V; Krolicki L Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910 [TBL] [Abstract][Full Text] [Related]
33. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan? Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540 [TBL] [Abstract][Full Text] [Related]
34. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies. Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571 [TBL] [Abstract][Full Text] [Related]
35. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan. Trybek T; Kowalska A; Lesiak J; Młynarczyk J Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108 [TBL] [Abstract][Full Text] [Related]
36. 124I PET/CT to Predict the Outcome of Blind 131I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET). Kist JW; de Keizer B; van der Vlies M; Brouwers AH; Huysmans DA; van der Zant FM; Hermsen R; Stokkel MP; Hoekstra OS; Vogel WV; ; J Nucl Med; 2016 May; 57(5):701-7. PubMed ID: 26609180 [TBL] [Abstract][Full Text] [Related]
37. The Rate and Clinical Significance of Incidental Thyroid Uptake as Detected by Gallium-68 DOTATATE Positron Emission Tomography/Computed Tomography. Nockel P; Millo C; Keutgen X; Klubo-Gwiezdzinska J; Shell J; Patel D; Nilubol N; Herscovitch P; Sadowski SM; Kebebew E Thyroid; 2016 Jun; 26(6):831-5. PubMed ID: 27094616 [TBL] [Abstract][Full Text] [Related]
38. Initial Clinical Investigation of [18F]Tetrafluoroborate PET/CT in Comparison to [124I]Iodine PET/CT for Imaging Thyroid Cancer. Samnick S; Al-Momani E; Schmid JS; Mottok A; Buck AK; Lapa C Clin Nucl Med; 2018 Mar; 43(3):162-167. PubMed ID: 29356744 [TBL] [Abstract][Full Text] [Related]
39. Head-to-Head Comparison of Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731 [No Abstract] [Full Text] [Related]
40. Comparison of FDG-PET and technetium-99m MIBI SPECT to detect metastatic cervical lymph nodes in well-differentiated thyroid carcinoma with elevated serum HTG but negative I-131 whole body scan. Wu HS; Huang WS; Liu YC; Yen RF; Shen YY; Kao CH Anticancer Res; 2003; 23(5b):4235-8. PubMed ID: 14666632 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]